What Is the Orphan Drug Designation Process in China for Foreign Companies?

China’s orphan drug designation pathway represents a significant opportunity for foreign pharmaceutical companies developing therapies for rare diseases. Since the implementation of the Drug Administration Law of 2019 and the subsequent release of implementing regulations, China has established a formal framework for orphan drug designation that includes expedited review, regulatory assistance, and market exclusivity benefits. For foreign companies navigating this landscape, understanding the specific designation criteria, application procedures, and strategic advantages is essential for successfully bringing rare disease treatments to the Chinese market.

Regulatory Foundations of Orphan Drug Designation in China

The legal basis for orphan drug regulation in China is established under several key documents. The Drug Administration Law (2019 Revision) introduced the concept of “drugs for rare diseases” and authorized the NMPA to develop expedited approval pathways. The NMPA’s Working Procedures for Drug Registration (2020) further defines the orphan drug designation process, while the Technical Guidelines for Clinical Trials of Drugs for Rare Diseases (2021) provides detailed guidance on clinical development programs for orphan indications.

The Center for Drug Evaluation (CDE) of the NMPA is the primary agency responsible for reviewing orphan drug designation applications. The National Health Commission (NHC), in coordination with the NMPA, maintains the official list of rare diseases in China, which serves as a reference for determining whether a condition qualifies for orphan drug designation.

Definition of Orphan Drug and Rare Disease in China

Unlike the United States, where a rare disease is defined by patient population (fewer than 200,000 patients), China employs a dual-definition approach. A rare disease in China is defined as:

• A disease affecting fewer than 1 in 10,000 people in China (approximately 140,000 patients nationally), or
• A disease with a prevalence below 500,000 patients in China, as determined by the NHC’s Expert Committee on Rare Diseases.

For a drug to qualify for orphan designation, it must be intended for the diagnosis, prevention, or treatment of a rare disease that appears on the official Rare Disease Catalogue maintained by the NHC. The catalogue was first published in 2018 with 121 rare diseases and expanded to 207 diseases in 2025. A drug may also qualify if it addresses a condition that does not appear on the catalogue but meets the statistical prevalence criteria.

Benefits of Orphan Drug Designation

Foreign companies that obtain orphan drug designation from the NMPA receive several significant advantages:

Expedited Review and Approval

Orphan drugs are eligible for priority review and approval under the NMPA’s expedited pathways. The standard drug registration review timeline of 200 working days can be reduced to as few as 60 to 100 working days for orphan-designated products. The CDE provides enhanced communication and guidance throughout the review process, including pre-submission meetings and milestone-based regulatory advice.

Reduced Clinical Trial Requirements

One of the most significant benefits is the potential for reduced clinical trial requirements. The CDE may accept smaller, shorter, or differently designed clinical trials for orphan drugs, including single-arm trials, historically controlled trials, or the use of real-world evidence (RWE) as supportive data. For drugs already approved in other jurisdictions (e.g., FDA or EMA orphan designations), the CDE may accept foreign clinical data with a limited China-specific bridging study, or in some cases, waive local clinical trials entirely.

Market Exclusivity

The 2019 Drug Administration Law introduced a market exclusivity period of up to 7 years for orphan drugs approved in China. During this exclusivity period, the NMPA will not accept or approve a separate application for the same drug for the same rare disease indication, providing a significant competitive advantage. The exact duration of exclusivity is determined on a case-by-case basis, with first-in-class or breakthrough therapies typically receiving the full 7-year period.

Regulatory Assistance and Fee Reductions

Orphan drug sponsors receive enhanced regulatory support, including dedicated CDE review teams, scientific advice meetings, and assistance with clinical trial design. Additionally, certain drug registration fees may be reduced or waived for orphan drug applications, though the specific fee schedule varies by drug type and application complexity.

The Orphan Drug Designation Application Process

Step 1: Pre-Submission Consultation

Before submitting a formal orphan drug designation application, foreign companies are strongly encouraged to request a pre-submission consultation meeting with the CDE. This meeting allows the sponsor to present their drug candidate, discuss the rare disease indication, and receive preliminary feedback on the suitability of the orphan drug designation pathway. The consultation typically requires submission of a briefing document 30 days before the scheduled meeting date.

Step 2: Compile the Application Dossier

The orphan drug designation application must include the following components:

• Disease background: Detailed description of the rare disease, including its epidemiology in China, disease burden, natural history, and current treatment options.
• Drug information: Chemical structure, mechanism of action, pharmacological profile, and manufacturing information.
• Non-clinical data: Summary of pharmacology, toxicology, and pharmacokinetic studies.
• Clinical data: Available clinical trial results, including foreign clinical data, with a discussion of how these data support the orphan indication.
• Regulatory status: Information on orphan designations or marketing approvals in other jurisdictions (FDA, EMA, PMDA, etc.).
• Development plan: Proposed clinical development plan for the Chinese market, including any planned bridging studies or local clinical trials.
• Rationale for orphan designation: Justification for why the drug meets the orphan drug criteria, including prevalence data and medical necessity arguments.

Step 3: Formal Application Submission

The formal application is submitted through the CDE’s online portal. For foreign companies, a China-based legal entity or authorized agent must be designated as the application sponsor. All application materials must be submitted in Chinese, though supporting documents may be provided in English with certified Chinese translations.

Step 4: CDE Review and Decision

The CDE reviews the application within 60 working days of submission. During this period, the CDE may request additional information or clarification. The review focuses on:

• Whether the disease meets the definition of a rare disease in China
• Whether the drug has a plausible therapeutic rationale for the rare disease indication
• The adequacy of available preclinical and clinical data to support the designation
• The overall feasibility of the proposed development plan for the Chinese market

Step 5: Designation and Ongoing Obligations

If approved, the CDE issues an orphan drug designation certificate. The designation is valid for the duration of the drug development program and remains in effect until marketing authorization is granted or the designation is withdrawn. Designated orphan drug sponsors must submit annual progress reports to the CDE, including updates on clinical development, manufacturing, and any changes to the regulatory status in other jurisdictions.

Strategic Considerations for Foreign Companies

Leveraging Foreign Regulatory Designations

The CDE places significant weight on orphan drug designations from established regulatory authorities such as the FDA, EMA, and Japan’s PMDA. A drug that has received orphan designation in two or more of these jurisdictions has a substantially higher probability of receiving designation in China. Foreign companies should include all international designation decisions in their application dossier.

Navigating the Rare Disease Catalogue

The NHC’s Rare Disease Catalogue is updated periodically, with the most recent expansion to 207 diseases in 2025. Foreign companies targeting rare diseases should monitor catalogue updates closely, as inclusion of a disease in the catalogue significantly simplifies the designation process. For diseases not yet on the catalogue, foreign companies can petition the NHC’s Expert Committee for inclusion, supported by epidemiological data demonstrating the disease’s prevalence in China.

Clinical Trial Strategy

The CDE has demonstrated increasing flexibility in accepting foreign clinical data for orphan drugs. The 2021 Technical Guidelines for Clinical Trials of Drugs for Rare Diseases explicitly acknowledge the challenges of conducting randomized controlled trials for rare diseases and provide guidance on alternative trial designs. Foreign companies should engage the CDE early to discuss an acceptable clinical data package, potentially avoiding the need for large-scale China-specific trials.

Pricing and Reimbursement Considerations

Orphan drug designation does not automatically guarantee favorable pricing or reimbursement in China. However, orphan drugs have been the subject of positive pricing policies in recent years. The National Healthcare Security Administration (NHSA) has included an increasing number of orphan drugs in the National Reimbursement Drug List (NRDL) through annual negotiations. As of 2026, over 60 orphan drugs have been included in the NRDL, with average price reductions of 40-60% negotiated through the national volume-based procurement process.

Conclusion

China’s orphan drug designation pathway offers foreign pharmaceutical companies a structured, increasingly accessible route to bring rare disease therapies to the world’s second-largest pharmaceutical market. The benefits of expedited review, reduced clinical trial requirements, market exclusivity, and regulatory support make orphan drug designation a strategic priority for any company developing treatments for rare diseases that affect Chinese patients. By understanding the designation criteria, preparing comprehensive application dossiers, and engaging proactively with the CDE, foreign companies can successfully navigate the orphan drug designation process and establish a competitive position in China’s growing rare disease treatment market.

Disclaimer: This article is for informational purposes and does not constitute legal or regulatory advice. Foreign pharmaceutical companies should consult with qualified regulatory affairs professionals and legal counsel for their specific orphan drug designation strategies.